학술논문
Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials.
Document Type
Article
Source
Subject
*PATIENT selection
*MELANOMA
*CLINICAL trials
*HUMAN research subjects
*IMMUNOTHERAPY
*CANCER patients
*MENINGEAL cancer
*METASTASIS
*STATISTICS
*ENDOWMENT of research
*BRAIN tumors
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0735-7907
Abstract
The CNS is a common site for distant metastasis and treatment failure in melanoma patients. This study aimed to evaluate the inclusion rate of patients with melanoma brain metastases (MBM) in prospective clinical trials. 69.3% of trials excluded MBM patients based on their CNS disease. In univariate analysis, trials not employing immunotherapy (p = 0.0174), inclusion of leptomeningeal disease (p < 0.0001) and non-pharmaceutical sponsor trials (p = 0.0461) were more likely to enroll patients with MBM. Thoughtful reconsideration of clinical trial designs is needed to give patients with MBMs access to promising investigational agents and improve outcomes for patients with MBM. [ABSTRACT FROM AUTHOR]